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Abstract
Introduction: Since 2015, the World Health Organization (WHO) has recommended that all people living with HIV (PLHIV)
initiate antiretroviral treatment (ART), irrespective of CD4+ count or clinical stage. National adoption of universal treatment
has accelerated since WHO’s 2015 “Treat All” recommendation; however, little is known about the translation of this guidance
into practice. This study aimed to assess the status of Treat All implementation across regions, countries, and levels of the
health care delivery system.
Methods: Between June and December 2017, 201/221 (91%) adult HIV treatment sites that participate in the global IeDEA
research consortium completed a survey on capacity and practices related to HIV care. Located in 41 countries across seven
geographic regions, sites provided information on the status and timing of site-level introduction of Treat All, as well as
site-level practices related to ART initiation.
Results: Almost all sites (93%) reported that they had begun implementing Treat All, and there were no statistically significant
differences in site-level Treat All introduction by health facility type, urban/rural location, sector (public/private) or country
income level. The median time between national policy adoption and site-level introduction was one month. In countries where
Treat All was not yet adopted in national guidelines, 69% of sites reported initiating all patients on ART, regardless of clinical
criteria, and these sites had been implementing Treat All for a median period of seven months at the time of the survey. The
majority of sites (77%) reported typically initiating patients on ART within 14 days of confirming diagnosis, with 60% to 62%
of sites implementing Treat All in East, Southern and West Africa reporting same-day ART initiation for most patients.
Conclusions: By mid- to late-2017, the Treat All strategy was the standard of care at almost all IeDEA sites, including rural,
primary-level health facilities in low-resource settings. While further assessments of site-level capacity to provide high-quality
HIV care under Treat All and to support sustained viral suppression after ART initiation are needed, the widespread introduc-
tion of Treat All at the service delivery level is a critical step towards global targets for ending the HIV epidemic as a public
health threat.
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1 | INTRODUCTION
WHO's 2015 recommendation [1] for immediate treatment
of all PLHIV, regardless of CD4+ cell count, represented a
paradigm shift in HIV care and treatment. By preventing
morbidity and mortality among PLHIV [2,3] and averting
new infections through onward transmission of the virus
[4–6], universal treatment of HIV (also known as “Treat All”
and “Test and Treat”) provides a clear strategy for ending
the HIV epidemic and for meeting the targets set by the
Joint United Nations Programme on HIV/AIDS in 2014 –
that is, ensuring that 90% of PLHIV know their status, with
90% of those who are diagnosed (and therefore eligible) on
combination ART, and 90% of those on ART achieving sus-
tained viral load suppression by 2020, with 95-95-95%
respectively, reaching these targets by 2030 [7,8].
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While evidence of the benefits of early treatment led a
few countries to adopt Treat All in national policy guidelines
prior to WHO’s 2015 recommendation (Figure 1), transla-
tion of WHO guidance into national policies and into clinical
practice at the service delivery level often lags, particularly
in low-resource settings. An analysis of 33 countries in sub-
Saharan Africa found that the time lag in national-level
adoption of WHO’s 2009 and 2013 HIV treatment guideli-
nes averaged 24 and 10 months, respectively [9]. Other
analyses of site-level implementation of prior WHO guideli-
nes have highlighted logistical challenges that contribute to
delays in translating policies into practice [10–12]. Although
available evidence suggests that by late 2017, most coun-
tries around the world had adopted some form of the
WHO’s Treat All guidance [13,14], little is known about the
timing of site-level introduction and how this varies across
regions and levels of health care delivery, or about site-level
capacity to appropriately initiate all enrolled patients on
ART.
Using data collected from health facilities that are part of
the International epidemiology Databases to Evaluate AIDS
(IeDEA) – a global collaboration that consolidates, curates and
analyses longitudinal data on care and treatment of PLHIV –
we sought to assess the status and timing of site-level Treat
All introduction for adult PLHIV across multiple regions and
countries. We also aimed to describe site-level practices
related to pre-ART counselling, the timing of ART initiation
and viral load monitoring capacity at sites where Treat All is
the standard of care.
2 | METHODS
2.1 | Data sources
2.1.1 | Data collection
IeDEA is an international research consortium of HIV care and
treatment sites in 46 countries across seven world regions: the
Asia-Pacific; the Caribbean, Central and South America; Central
Africa; East Africa; Southern Africa; West Africa; and North
America [15]. IeDEA is a purely observational research consor-
tium that does not dictate policies or practices to participating
HIV care and treatment clinics. IeDEA regularly conducts gen-
eral and specialized surveys in order to characterize the attri-
butes, capacity and services available at sites that participate in
the consortium [16,17].
Between June and December 2017, a cross-sectional 115-
item survey was administered in English or French to 255 active
HIV care and treatment clinics that contribute longitudinal
patient-level data to IeDEA. In Southern Africa, where many
IeDEA sites contribute data as part of a programmatic cohort
that follows uniform practices across all clinics, one site from
each cohort was surveyed; accordingly, four cohort-representa-
tive sites were surveyed in Lesotho, Mozambique, Zambia and
Zimbabwe, representing 8, 17, 105 and 35 clinics respectively,
within each country’s active observational cohorts.
The survey was distributed in paper form and as an online
questionnaire. REDCap electronic data capture tools hosted
at Vanderbilt University Medical Center [18] were used to
implement the online version of the survey. Surveys com-
pleted on paper were entered into REDCap by regional repre-
sentatives. All sites and IeDEA regional coordinating centres
had IRB approvals in place permitting the collection of site-
level data for the survey.
2.1.2 | Site-level characteristics and practices related
to Treat All
The survey explored the current criteria used for initiating
ART and the month and year those guidelines were intro-
duced at the service delivery site. Adult treatment sites
were considered as having implemented the Treat All policy
if they reported that they currently “Start all patients on
ART regardless of CD4+ cell count or symptoms.” Sites
reporting that they only “Start some patients on ART regard-
less of CD4+ cell count or symptoms” – for example,
patients with a pregnancy or coinfection with tuberculosis or
hepatitis B – were not considered to be implementing Treat
All.
Other survey items included questions related to facility
attributes, including location (urban vs. rural), level (e.g. health
centre, district hospital, regional/provincial and teaching hospi-
tal), and sector (public vs. private). The survey also explored
routine site-level practices related to pre-ART counselling,
ART initiation and viral load monitoring. Sites that reported
that they could routinely request or perform viral load (quanti-
tative HIV RNA) testing were considered to have the capacity
for viral load monitoring among patients initiating ART.
2.1.3 | National HIV treatment guidelines and setting
characteristics
To determine dates of national adoption of Treat All, we con-
ducted a systematic search of health ministry websites for
national HIV treatment guidelines, policies, notices, and press
releases related to Treat All. When policy documents were
unavailable or specified only the year of Treat All adoption,
the date of policy adoption was assessed based on other
sources, including the International Association of Providers of
AIDS Care (IAPAC) Global HIV Policy Watch [19] and country
operational plans (COPs) of the United States President’s
Emergency Plan for AIDS Relief (PEPFAR), as well as in-
2003 
WHO CD4 count 
≤200 cells per μL
2009 
WHO CD4 count 
≤350 cells per μL
2012 
USA & Canada 
introduce Treat 
All
2013 
WHO CD4 count 
≤500 cells per μL
South Korea  & 
Brazil introduce 
Treat All
2014 
Thailand 
introduces Treat 
All
2015 
WHO Treat All 
recommendaon
Figure 1. Timing of major HIV treatment guideline changes, including universal treatment of people living with HIV.
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country researchers and national treatment programme staff
affiliated with IeDEA.
As national HIV treatment guideline changes were ongoing
in 2017, we considered the national guideline to be that which
was in place at the time each site completed the survey. Sites
were considered to be subject to a national Treat All policy if
they completed the survey after universal HIV treatment had
been officially adopted in published national guidelines. Sites
were considered to be operating within a pre-Treat All policy
context if they completed the survey before the date of
national Treat All adoption.
We collected information on each country’s income group
classification in 2017 from World Bank databases [20] and
status as a PEPFAR- and/or Global Fund to Fight AIDS, Tuber-
culosis and Malaria (Global Fund)-supported country respec-
tively, from the PEPFAR and Global Fund websites [21,22].
Countries with a PEPFAR country operational plan for 2017
were considered PEPFAR-supported countries, and countries
with a 2017 funding allocation were considered Global-fund
supported countries.
2.2 | Statistical analysis
Analyses included descriptive statistics (frequency calculations,
median year of site-level Treat All implementation and median
intervals – in months – between national guideline adoption
and site-level implementation). Frequencies of site-level imple-
mentation of Treat All were stratified by site characteristics,
country characteristics, and region, with Fisher’s exact tests
used to assess independence. The Wilcoxon test was used to
compare medians. All statistical analyses were performed
using SAS 9.4 (SAS Institute, Cary, NC), and ArcGIS Desktop
10.6 (Environmental Systems Research Institute, Redlands,
CA) was used for descriptive mapping.
Sites that did not report the month of site-level Treat All
introduction were included in frequency calculations of the
timing of Treat All introduction relative to (i.e. before/after)
national guideline adoption if the year of site-level introduc-
tion differed from the year of national guideline adoption.
Sites were excluded if the year of site-level introduction was
the same as that of national adoption because there was no
way to verify whether these sites began implementation
before or after the national guideline adoption.
The interval between national guideline adoption and site-level
introduction was assessed as the time in months between the
publication of updated national treatment guidelines that
reflected Treat All and the month that each site reported begin-
ning to provide ART to all HIV patients, regardless of CD4+ cell
count or clinical disease staging. In countries where Treat All was
not incorporated in national guidelines, we assessed the time, in
months, between site-level introduction of Treat All and the date
the survey was completed as the duration of implementation.
Sites that were unable to report both month and year of Treat
All introduction were excluded from these analyses.
3 | RESULTS
Responses to the IeDEA Site Assessment survey were
received from 234/255 IeDEA sites, including 201/221 sites
(91%) in 41 countries that provide HIV care to adult patients.
Thirty-four sites providing services to paediatric patients only
were excluded from the analysis because the timing of Treat
All guidance for paediatric patients differed from that for
adult patients.
3.1 | Site-level Treat All implementation
Overall, 93% of adult HIV treatment sites (187/201) reported
that they currently initiate all patients on ART, irrespective of
CD4+ cell count or WHO clinical stage (see Table 1). All
IeDEA sites in the Caribbean, Central and South America and
in East Africa regions reported implementing Treat All, as did
the vast majority of sites in the Southern Africa, North Amer-
ica, Central Africa and Asia-Pacific regions. In contrast, in the
West Africa region – where national policies at the time of
the survey did not reflect Treat All adoption in any country –
63% of sites reported that all patients were initiated on HIV
treatment. There were no statistically significant differences in
site-level Treat All implementation by health facility type,
urban/rural location, sector (public vs. private), country income
group or PEPFAR/Global Fund-support status.
In countries where universal treatment of PLHIV had been
adopted in national treatment guidelines (26/41 countries),
site-level implementation of Treat All was almost universal
(97%, 169/175 sites), and there were no significant differ-
ences in site-level implementation by country income designa-
tion or PEPFAR-support status, or by facility type, location or
sector. Site-level implementation of Treat All was significantly
lower in countries where universal HIV treatment had not yet
been incorporated into national guidelines (15/41 countries)
at the time of the survey (69%, 18/26 sites), compared to
countries where Treat All was adopted in national treatment
guidelines (97%, 169/175 sites, p < 0.0001).
3.2 | Timing of site-level Treat All introduction
Among 178 sites that reported the year they began imple-
menting Treat All, the year of site-level introduction of Treat
All ranged from 2008 to 2017 (Median year: 2016; IQR:
2015 to 2016) (Table 2). The median year of site-level Treat
All introduction was earliest in the North America (2014),
Asia-Pacific (2015), and Caribbean, Central and South America
(2015) regions, and latest among sites in the West Africa
region (2017). The median year of site-level Treat All introduc-
tion was earlier at higher-level health facilities (e.g. regional/
provincial and teaching hospitals), private sector facilities, and
sites located in high-income, non-PEPFAR-supported countries.
At the country level, the median year of site-level Treat All
introduction ranged from 2011 to 2017 (Figure 2 and
Table S1). In several countries where Treat All had not been
adopted nationally at the time of the survey (e.g. Burkina
Faso, Republic of the Congo, Senegal, Mozambique, Indonesia
and Vietnam), none of the surveyed sites had introduced Treat
All.
Almost all sites (178/187, 95%) reporting implementation
of Treat All specified the year of site-level introduction, and
81% (152/187) reported both month and year of site-level
introduction. Just over one-third (35%) of sites reported that
they began initiating all patients on ART regardless of immune
status or clinical disease stage prior to the adoption of Treat
All in national guidelines (Table 1). Site-level introduction of
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Table 1. Implementation of Treat All at IeDEA sites, by national guideline status
Participating sites Sites implementing Treat All
Sites implementing
Treat All prior to
national guideline
changea (N = 170)All sites
In countries
with national
adoption
of Treat All
In countries
without
national
adoption of
Treat All
All sites
(N = 201)
In countries
with national
adoption
of Treat
All (N = 175)
In countries
without
national
adoption of
Treat All
(N = 26)
All sites 201 (100%) 175 (87.1%) 26 (12.9%) 187 (93.0%) 169 (96.6%) 18 (69.2%) 59 (34.7%)
IeDEA region [Fisher’s exact test p-value] [p = 0.004] [p = 0.446] [p = 0.309] [p < 0.0001]
Asia-Pacific 42 (20.9%) 34 (81%) 8 (19%) 36 (85.7%) 31 (91.2%) 5 (62.5%) 21 (65.6%)
Caribbean,
Central and
South America
14 (7.0%) 10 (71.4%) 4 (28.6%) 14 (100%) 10 (100%) 4 (100%) 6 (50%)
Central Africa 19 (9.5%) 16 (84.2%) 3 (15.8%) 17 (89.5%) 16 (100%) 1 (33.3%) 3 (17.6%)
East Africa 42 (20.9%) 39 (92.9%) 3 (7.1%) 42 (100%) 39 (100%) 3 (100%) 13 (33.3%)
North America 41 (20.4%) 41 (100%) 0 (0%) 39 (95.1%) 39 (95.1%) 0 (0%) 11 (35.5%)
Southern Africa 35 (17.4%) 35 (100%) 0 (0%) 34 (97.1%) 34 (97.1%) 0 (0%) 0 (0%)
West Africa 8 (4.0%) 0 (0%) 8 (100%) 5 (62.5%) 0 (0%) 5 (62.5%) 5 (100%)
Health facility type [p = 0.131] [p = 0.363] [p = 0.628] [p = 0.011]
Primary (health centre) 101 (50.2%) 96 (95%) 5 (5%) 97 (96%) 94 (97.9%) 3 (60.0%) 22 (24.7%)
District hospital 18 (9.0%) 18 (100%) 0 (0%) 17 (94.4%) 17 (94.4%) 0 (0%) 6 (37.5%)
Regional/provincial
or teaching hospital
82 (40.8%) 61 (74.4%) 21 (25.6%) 73 (89%) 58 (95.1%) 15 (71.4%) 31 (47.7%)
Sector [p = 0.703] [p = 1.00] [p = 1.00] [p = 0.129]
Public 169 (84.1%) 144 (85.2%) 25 (14.8%) 156 (92.3%) 139 (96.5%) 17 (68.0%) 45 (31.9%)
Private 32 (15.9%) 31 (96.9%) 1 (3.1%) 31 (96.9%) 30 (96.8%) 1 (100%) 14 (48.3%)
Facility location [p = 0.121] [p = 0.673] [p = 1.00] [p < 0.0001]
Urban/Mostly urban 149 (74.1%) 124 (83.2%) 25 (16.8%) 136 (91.3%) 119 (96.1%) 17 (68.0%) 54 (44.3%)
Rural/Mostly rural 52 (25.9%) 51 (98.1%) 1 (1.9%) 51 (98.1%) 50 (98.0%) 1 (100%) 5 (10.4%)
Country income group [p = 0.751] [p = 0.410] [p = 0.453] [p < 0.0001]
Low income 58 (28.9%) 50 (86.2%) 8 (13.8%) 54 (93.1%) 49 (98.0%) 5 (62.5%) 6 (11.1%)
Lower-middle income 49 (24.4%) 37 (75.5%) 12 (24.5%) 44 (89.8%) 37 (100%) 7 (58.3%) 19 (47.5%)
Upper-middle income 29 (14.4%) 27 (93.1%) 2 (6.9%) 28 (96.6%) 26 (96.3%) 2 (100%) 9 (34.6%)
High income 65 (32.3%) 61 (93.8%) 4 (6.2%) 61 (93.8%) 57 (93.4%) 4 (100%) 25 (50%)
PEPFAR-supported country [p = 0.093] [p = 0.094] [p = 0.683] [p < 0.0001]
No 94 (46.8%) 80 (85.1%) 14 (14.9%) 84 (89.4%) 75 (93.8%) 9 (64.3%) 37 (52.1%)
Yes 107 (53.2%) 95 (88.8%) 12 (11.2%) 103 (96.3%) 94 (98.9%) 9 (75.0%) 22 (22.2%)
GFATM-supported country [p = 0.574] [p = 0.231] [p = 0.277] [p < 0.0003]
No 76 (37.8%) 72 (94.7%) 4 (5.3%) 72 (94.7%) 68 (94.4%) 4 (100%) 30 (50.0%)
Yes 125 (62.2%) 103 (82.4%) 22 (17.6%) 115 (92.0%) 101 (98.1%) 14 (63.6%) 29 (26.4%)
Year of national Treat All adoption [p < 0.0001] [p = 0.060] - [p < 0.0001]
2012 (2 countries) 41 (20.4%) 41 (100%) - 39 (95.1%) 39 (95.1%) - 11 (35.5%)
2013 (2 countries) 8 (4.0%) 8 (100%) - 8 (100%) 8 (100%) - 4 (50%)
2014 (2 countries) 6 (3.0%) 6 (100%) - 6 (100%) 6 (100%) - 1 (16.7%)
2015 (2 countries) 18 (9.0%) 18 (100%) - 16 (88.9%) 16 (88.9%) - 8 (61.5%)
2016 (16 countries) 97 (48.3%) 97 (100%) - 96 (99.0%) 96 (99.0%) - 15 (16.3%)
2017 (2 countries) 5 (2.5%) 5 (100%) - 4 (80.0%) 4 (80.0%) - 4 (100%)
Treat All not adopted
nationallyb (15 countries)
26 (12.9%) - 26 (100%) 18 (69.2%) 0 (0%) 18 (100%) 16 (100%)
aSites with known month and year of Treat All introduction; bsites in countries that adopted Treat All in 2017 after the survey was completed
counted among sites where Treat All was not yet adopted nationally.
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Treat All prior to national guideline adoption was significantly
more common among district, regional/provincial and teaching
hospitals (37/81, or 46%) than primary-level health centres
(22/89, or 25%; p = 0.006) and at sites in urban areas (54/
122, or 44%), compared with rural sites (5/48 or 10%;
p < 0.0001). All Treat All-implementing sites in the West
Africa region (100%) and almost two-thirds of sites in the
Asia-Pacific region reported that site-level introduction of
Treat All preceded national guideline adoption, as did half of
the surveyed sites in the Caribbean, Central and South Amer-
ica and about one-third of sites in the East Africa and North
America regions. In contrast, no sites in Southern Africa and
few sites in Central Africa reported implementing Treat All
prior to national guideline adoption.
3.3 | Time from national adoption of Treat All to
site-level introduction
In countries where Treat All had been adopted nationally, 138/
175 (79%) sites reported both month and year of Treat All
introduction. Among these sites, the median time lag between
national guideline adoption and site-level introduction was 1
month (IQR: 1 to 4 months) (Table 2). Intervals between
national guideline adoption and site-level introduction were sig-
nificantly longer at rural sites (median time 2 months; IQR: 2 to
3 months) compared with urban sites (median time zero
months; IQR: 6 to 5 months; p < 0.001) and at public sector
sites (median time 2 months; IQR: 0 to 5 months) compared
with private sector facilities (median time 0 months; IQR: 50
to 2 months; p = 0.0046). The time to site-level introduction of
Treat All was also longer in low- and lower-middle-income
countries (median time 2 months; IQR: 0 to 2.5 months), com-
pared with high- and upper-middle-income countries (median
time 0 months; IQR: 9 to 16 months) and in PEPFAR-
supported countries (median time 2 months; IQR: 0 to 2
months) compared with non-PEPFAR-supported countries
(median time 1 month; IQR: 13 to 21 months); however,
these differences were not statistically significant, given wide
variation in the timing of Treat All in high- and upper-
middle-income countries. Similarly, the time to site-level intro-
duction of Treat All was longer at health centres (median time
2 months; IQR: 0 to 2 months), compared with district,
regional/provincial and teaching hospitals (median time one
month; IQR: 4 to 12 months) (differences not statistically
significant).
In countries where national Treat All policies had not yet
been adopted, 14/26 sites that were treating all patients irre-
spective of CD4+ counts or other symptoms reported that
they had been initiating all patients on ART for a median per-
iod of seven months at the time of the survey (IQR: 13 to
6 months).
3.4 | ART initiation practices and viral load
monitoring at Treat All-implementing sites
Approximately two-thirds (66%) of sites implementing Treat
All reported that they typically conduct one to two adherence
counselling sessions prior to initiating patients on ART, while
24% (45/187) reported providing three or more such sessions
(Table 3), and 10% (19/187) reported that patients typically
have no pre-ART counselling sessions. Private sector sites
were significantly more likely than public sector sites to report
no adherence counselling sessions prior to ART initiation
(29% vs. 6%; p < 0.001), as were sites in urban areas com-
pared to rural areas (13% vs. 2%; p = 0.03). Sites in high-
income countries and countries not supported by PEPFAR or
the Global Fund were also significantly more likely to report
that patients typically have no pre-ART counselling sessions
(21% to 28% vs. 1% to 2%; p < 0.05). Among the 14 sites
that had not yet introduced Treat All, half (7/14) reported
that they typically conduct one to two counselling sessions
before initiating patients on ART, with six sites reporting that
patients typically have three or more counselling sessions
prior to initiating treatment.
Among 187 sites implementing Treat All, 77% reported ini-
tiating patients on ART within 14 days of establishing treat-
ment eligibility (Table 3). Same-day ART initiation was more
commonly reported by sites in the East, Southern, and West
Africa regions (60% to 62%), as well as by district hospitals
(12/17, or 71%) and public sector sites (66/156, or 42%). In
contrast, almost half of private sector facilities (13/31, or
42%) reported that patients did not initiate ART until two to
four weeks or longer after confirming HIV diagnosis, as did
sites in high-income countries (30/61, or 49%), in countries
not supported by PEPFAR (38/84, or 45%) or the Global Fund
(34/72, or 47%), and in countries where Treat All was
adopted in national guidelines before WHO’s 2015 recom-
mendation (23/69, or 46%). More than one quarter (11/43 or
26%) of the sites reporting that they initiate patients on ART
two to four weeks or longer after confirming diagnosis also
reported that typically they do not conduct adherence coun-
selling sessions prior to ART initiation; in contrast, only 7% (5/
72) sites reporting same day ART initiation reported that their
patients typically do not attend any pre-ART counselling ses-
sions.
More than two-thirds of sites implementing Treat All (129/
187) reported that viral load testing was available as part of
routine care of patients at the site. Viral load testing capacity
was nearly universal among sites in high-income (59/61, or
97%) and upper-middle-income countries (26/28, or 93%).
However, only 39% (21/54) of sites in low-income countries
and 52% (23/44) of sites in lower-middle-income countries
reported that viral load testing was available as part of routine
patient care. Capacity for routine viral load monitoring was
also significantly more common among urban sites compared
with rural sites (110/136 (81%) vs. 19/51 (37%); p < 0.0001);
and in hospitals (district, regional/provincial or teaching hospi-
tals) compared with health centres (74/90 (82%) vs. 55/97
(57%); p < 0.001).
4 | DISCUSSION
Surveying 201 adult HIV treatment sites that participate in
the global IeDEA collaboration across 41 countries, this study
found that the vast majority of sites had begun initiating all
patients on ART by mid-2017, regardless of immune status or
clinical disease stage. Site-level implementation of Treat All is
almost universal in countries that have incorporated WHO’s
2015 recommendation into national guidelines. Previous
research has highlighted various logistical barriers and health
system constraints, such as guideline dissemination, training of
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Table 2. Timing and length of Treat All implementation at IeDEA sites
Timing of Treat All
implementation (sites with known
year of implementation)
Time (in months) from
national adoption to site
implementationa in
countries where Treat All
adopted nationally
Length of
implementation (in
months) among sites in
countries where Treat
All not yet adopted
nationally
N Median [IQR] N Median [IQR] N Median [IQR]
All sites 178 2016 [2015 to 2016] 138 1 [1, 4] 14 7.4 [5.6, 12.7]
IeDEA region
Asia-Pacific 35 2015 [2014 to 2016] 24 2 [12, 5] 3 3.3 [0.6, 5.6]
Caribbean, Central and South America 13 2015 [2013 to 2016] 16 0 [0, 1] 2 10 [3.9, 16.1]
Central Africa 17 2016 [2016 to 2016] 9 0 [1, 16] 1 9.9 [9.9, 9.9]
East Africa 41 2016 [2016 to 2017] 33 2 [1, 7] 3 17.5 [8.7, 19.7]
North America 33 2014 [2010 to 2015] 22 11 [35, 40] 0 -
Southern Africa 34 2016 [2016 to 2016] 34 2 [1, 2] 0 -
West Africa 5 2017 [2017 to 2017] 0 - 5 6.7 [6.4, 8]
Health facility type
Primary (health center) 92 2016 [2016 to 2016] 79 2 [0, 2] 3 6.4 [5.7, 19.7]
District hospital 17 2016 [2016 to 2016] 14 2 [1, 3] 0 -
Regional/provincial or teaching hospital 69 2015 [2014 to 2016] 45 1 [9, 12] 11 8 [3.9, 12.7]
Sector
Public 148 2016 [2015 to 2016] 113 2 [0, 5] 13 8 [5.6, 12.7]
Private 30 2015 [2011 to 2016] 25 0 [50, 2] 1 6.7 [6.7, 6.7]
Facility location
Urban/Mostly urban 128 2016 [2014.5 to 2016] 91 0 [6, 5] 13 6.7 [5.6, 9.9]
Rural/Mostly rural 50 2016 [2016 to 2016] 47 2 [2, 3] 1 19.7 [19.7, 19.7]
Country income group
Low income 54 2016 [2016 to 2017] 49 2 [1, 2] 5 12.7 [9.9, 17.5]
Lower-middle income 42 2016 [2016 to 2016] 31 1 [1, 3] 5 6.4 [5.7, 6.7]
Upper-middle income 27 2016 [2015 to 2016] 24 0 [3.5, 7] 1 3.9 [3.9, 3.9]
High income 55 2015 [2012 to 2015] 34 1 [21, 27] 3 5.6 [0.6, 16.1]
PEPFAR-supported country
No 77 2015 [2014 to 2016] 50 1 [13, 21] 6 4.7 [3.3, 12.7]
Yes 101 2016 [2016 to 2016] 88 2 [0, 2] 8 8.4 [6.6, 13.7]
GFATM-supported country
No 66 2015 [2013 to 2015] 44 1 [12.5, 22] 3 5.6 [0.6, 16.1]
Yes 112 2016 [2016 to 2016] 94 2 [0, 2] 11 8.0 [5.7, 12.7]
Year of national Treat All adoption
2012 (2 countries) 33 2014 [2010 to 2015] 22 11 [35, 40] - -
2013 (2 countries) 8 2013 [2013 to 2015] 8 0.5 [9, 18.5] - -
2014 (2 countries) 6 2015 [2014 to 2016] 5 12 [0, 12] - -
2015 (2 countries) 16 2015 [2014.5 to 2015.5] 10 1 [7, 5] - -
2016 (16 countries) 95 2016 [2016 to 2016] 89 2 [0, 2] - -
2017 (2 countries) 4 2013.5 [2011.5 to 2015.5] 4 40.5 [63, 18] - -
Timing of national Treat All adoptionb
Before WHO recommendation 63 2015 [2013 to 2015] 45 0 [9, 22] - -
After WHO recommendation 99 2016 [2016 to 2016] 93 2 [0, 2] - -
Treat All not adopted nationally 16 2016.5 [2016 to 2017] - - 14 7.4 [5.6, 12.7]
aSites with known month and year of Treat All introduction; btiming relative to WHO recommendation of September 2015.
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health personnel, drug stockouts and gaps in laboratory capabil-
ities, which contributed to delays in implementing prior, CD4
count–based treatment guidelines [10,12,23]. However, our
study found that the time from national adoption to site-level
introduction was relatively rapid across IeDEA-participating
sites in 41 countries, with a median time-to-implementation of
one month. In countries where Treat All was adopted in national
guidelines in 2017, all IeDEA sites had begun implementing
WHO’s guidance in advance of national guideline changes.
Likely reasons for the rapid roll-out of Treat All at the service
delivery level may include temporal improvements in the capac-
ity to deliver ART across health systems, as well as the possibil-
ity that Treat All simplifies the provision of HIV treatment in
low-resourced health systems (38, 39).
In countries that officially adopted the Treat All policy prior
to WHO’s 2015 guidance, there was greater between-site
variation in the timing of site-level introduction of Treat All,
with implementation lags ranging from one to five years after
national policy adoption. In these predominately high-income
countries, variation in site-level introduction may reflect
heterogeneous health policy environments, decentralized
health systems, and a higher proportion of private-sector sites
operating autonomously. Earlier site-level adoption of Treat All
in these countries may reflect the feasibility of expanding HIV
treatment, given lower HIV prevalence, higher-resourced
health systems, and stronger logistics systems in these set-
tings [23,24], whereas later site-level introduction in these
countries may reflect barriers, such as gaps in providers’
Median year of Treat All implementation
2011
2013
2014
2015
2016
2017
non-IeDEA country
0% of sites implementing Treat All
North America
(N=41)†
Caribbean, 
Central & South 
America (N=14)
West Africa
(N=8)
Central Africa
(N=19)
Southern 
Africa (N=35)
East Africa 
(N=42)
Asia-Pacific 
(N=42)
Canada (11)
United States 
(30)
Argentina (1)
Brazil (7)
Chile (1)
Honduras (1)
Haiti (1)
Mexico (1)
Peru (2)
Benin (2)
Burkina Faso 
(1)
Cote d’Ivoire 
(4)
Senegal (1)
Burundi (3)
Cameroon (3)
Democratic Republic 
of Congo (1)
Republic of the 
Congo (2)
Rwanda (10)
Lesotho‡ (1)
Mozambique‡
(1)
Malawi (22)
South Africa (8)
Zambia‡ (1)
Zimbabwe‡ (2)
Kenya (28)
Tanzania (3)
Uganda (11)
Australia (17)
Cambodia (2)
China (2)
India (2)
Indonesia (2)
Japan (1)
Korea (1)
Malaysia (3)
New Zealand (2)
Philippines (1)
Singapore (1)
Taiwan (1)
Thailand (5)
Vietnam (2)
† Numbers in parentheses indicate the number of sites surveyed per country. 
‡ Indicates that a surveyed site represents a cohort of sites.
Figure 2. Median year of site-level implementation of Treat All among 201 IeDEA sites.
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Table 3. ART initiation practices and viral load testing capacity at 187 IeDEA sites implementing Treat All
Counseling sessions prior to ART
initiation Timing of ART initiation
Viral loada
testing routinely
available N (%)
0 sessions
N (%)
1 to 2
sessions
N (%)
≥3 sessions
N (%)
Same day
start N (%)
1 to 14 days
N (%)
2 to 4 weeks
or >1 month
N (%)
All sites 19 (10.2%) 123 (65.8%) 45 (24.1%) 73 (39%) 71 (38%) 43 (23.0%) 129 (69%)
IeDEA region [p < 0.0001]
Asia-Pacific 3 (8.3%) 27 (75%) 6 (16.7%) 3 (8.3%) 19 (52.8%) 14 (38.9%) 33 (91.7%)
Caribbean,
Central and
South America
0 (0%) 14 (100%) 0 (0%) 5 (35.7%) 4 (28.6%) 5 (35.7%) 12 (85.7%)
Central Africa 0 (0%) 8 (47.1%) 9 (52.9%) 4 (23.5%) 13 (76.5%) 0 (0%) 5 (29.4%)
East Africa 0 (0%) 19 (45.2%) 23 (54.8%) 26 (61.9%) 16 (38.1%) 0 (0%) 23 (54.8%)
North America 15 (38.5%) 22 (56.4%) 2 (5.1%) 11 (28.2%) 10 (25.6%) 18 (46.2%) 38 (97.4%)
Southern Africa 1 (2.9%) 28 (82.4%) 5 (14.7%) 21 (61.8%) 8 (23.5%) 5 (14.7%) 15 (44.1%)
West Africa 0 (0%) 5 (100%) 0 (0%) 3 (60%) 1 (20%) 1 (20%) 3 (60.0%)
Health facility type [p = 0.006] [p = 0.036] [p < 0.0001]
Primary (health
center)
12 (12.4%) 61 (62.9%) 24 (24.7%) 39 (40.2%) 39 (40.2%) 19 (19.6%) 55 (56.7%)
District hospital 0 (0%) 7 (41.2%) 10 (58.8%) 12 (70.6%) 3 (17.6%) 2 (11.8%) 11 (64.7%)
Regional/provincial
or teaching hospital
7 (9.6%) 55 (75.3%) 11 (15.1%) 22 (30.1%) 29 (39.7%) 22 (30.1%) 63 (86.3%)
Sector [p = 0.001] [p = 0.019] [p = 0.142]
Public 10 (6.4%) 104 (66.7%) 42 (26.9%) 66 (42.3%) 60 (38.5%) 30 (19.2%) 104 (66.7%)
Private 9 (29%) 19 (61.3%) 3 (9.7%) 7 (22.6%) 11 (35.5%) 13 (41.9%) 25 (80.6%)
Facility location [p = 0.033] [p < 0.0001] [p < 0.0001]
Urban/mostly urban 18 (13.2%) 89 (65.4%) 29 (21.3%) 40 (29.4%) 54 (39.7%) 42 (30.9%) 110 (80.9%)
Rural/mostly rural 1 (2%) 34 (66.7%) 16 (31.4%) 33 (64.7%) 17 (33.3%) 1 (2%) 19 (37.3%)
Country income group [p < 0.0001] [p < 0.0001] [p < 0.0001]
Low income 1 (1.9%) 39 (72.2%) 14 (25.9%) 23 (42.6%) 28 (51.9%) 3 (5.6%) 21 (38.9%)
Lower-middle income 0 (0%) 20 (45.5%) 24 (54.5%) 31 (70.5%) 13 (29.5%) 0 (0%) 23 (52.3%)
Upper-middle income 1 (3.6%) 24 (85.7%) 3 (10.7%) 5 (17.9%) 13 (46.4%) 10 (35.7%) 26 (92.9%)
High income 17 (27.9%) 40 (65.6%) 4 (6.6%) 14 (23%) 17 (27.9%) 30 (49.2%) 59 (96.7%)
PEPFAR-supported country [p < 0.0001] [p < 0.0001] [p < 0.0001]
No 18 (21.4%) 61 (72.6%) 5 (6%) 18 (21.4%) 28 (33.3%) 38 (45.2%) 80 (95.2%)
Yes 1 (1%) 62 (60.2%) 40 (38.8%) 55 (53.4%) 43 (41.8%) 5 (4.9%) 49 (47.6%)
GFATM-supported country [p < 0.0001] [p < 0.0001] [p < 0.0001]
No 17 (23.6%) 51 (70.8%) 4 (5.6%) 17 (23.6%) 21 (29.2%) 34 (47.2%) 70 (97.2%)
Yes 2 (1.7%) 72 (62.6%) 41 (35.7%) 56 (48.7%) 50 (43.5%) 9 (7.8%) 59 (51.3%)
Year of national Treat All adoption [p < 0.0001]
2012 (2 countries) 15 (38.5%) 22 (56.4%) 2 (5.1%) 11 (28.2%) 10 (25.6%) 18 (46.2%) 38 (97.4%)
2013 (2 countries) 0 (0%) 8 (100%) 0 (0%) 3 (37.5%) 2 (25.0%) 3 (37.5%) 8 (100%)
2014 (2 countries) 1 (16.7%) 4 (66.7%) 1 (16.7%) 0 (0%) 4 (66.7%) 2 (33.3%) 6 (100%)
2015 (2 countries) 2 (12.5%) 14 (87.5%) 0 (0%) 1 (6.3%) 6 (37.5%) 9 (56.3%) 15 (93.8%)
2016 (16 countries) 1 (1.0%) 57 (59.4%) 38 (39.6%) 52 (54.2%) 38 (39.6%) 6 (6.3%) 45 (46.9%)
2017 (2 countries) 0 (0%) 3 (75.0%) 1 (25.0%) 1 (25.0%) 2 (50.0%) 1 (25.0%) 4 (100%)
Treat All not adopted
nationallyb (15 countries)
0 (0%) 15 (83.3%) 3 (16.7%) 5 (27.8%) 9 (50.0%) 4 (22.2%) 13 (72.2%)
Timing of national
Treat All adoptionc
[p < 0.0001] [p < 0.0001] [p < 0.0001]
Before WHO
recommendation
18 (26.1%) 48 (69.6%) 3 (4.3%) 15 (21.7%) 22 (31.9%) 32 (46.4%) 67 (97.1%)
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knowledge, or lingering provider concerns about potential
negative consequences, such as the emergence of resistance,
treatment side effects, increased sexual risk-taking and lack of
patient-readiness [25–28]. In contrast, there was less
between-site variation in time-to-implementation in countries
adopting Treat All after WHO’s 2015 recommendation, espe-
cially in low-/lower-middle-income countries supported by
PEPFAR and/or the Global Fund, suggesting that site-level
roll-out of Treat All may be more uniform in countries receiv-
ing support from these and other donors [29].
The majority of surveyed sites in low- and lower-middle-
income countries reported typically starting patients on ART
within 14 days of eligibility ascertainment, which is promising,
given evidence that rapid ART initiation leads to improved
clinical outcomes [30,31]. Surprisingly, in high-income coun-
tries and countries with earlier national adoption of Treat All,
sites were more likely to report that patients generally initiate
ART two to four weeks or more after diagnosis is confirmed,
possibly reflecting heterogeneous provider practices in these
contexts, genotypic resistance testing, organ function testing,
or delays incurred in the coordination of multiple stakehold-
ers, including service delivery and insurance providers, prior
to treatment initiation [32–35]. Interestingly, sites that
reported longer times between enrolment and ART initiation
were also more likely to report that their patients typically
had no treatment readiness counselling sessions prior to
treatment initiation, suggesting these are not a likely source
of delay in initiating patients on ART.
Our study provides important early data assessing the
timing of Treat All introduction at the service delivery
level, as well as the interval between national guideline
adoption and site-level introduction. With a sample of 201
sites serving adult HIV patients across 41 countries, the
IeDEA site assessment reflects the status of Treat All roll-
out among a large and diverse sample of HIV care and
treatment sites across different regions, countries and
types of facilities. While almost all sites reported universal
HIV treatment as the standard of care, we found consider-
able variation in site-level practices related to rapid ART
initiation, with private sector sites and sites in high-
resource settings more likely to report longer times to
treatment initiation. Consistent with other research
[16,36–38], we also found considerable variation in capacity
for viral load monitoring, and almost one-third of the sites
implementing Treat All indicated that they could not rou-
tinely request or perform viral load testing. Such gaps
were particularly prevalent among sites located in rural
areas and in low-income countries, as well as in countries
where Treat All was adopted more recently. Our findings
also underscore the need to identify and address bottle-
necks, including health care payment systems, administra-
tive processes, and provider practices, that contribute to
delays in initiating patients on treatment, as well as those
contributing to suboptimal levels of treatment adherence
and sustained viral suppression (e.g. stockouts of antiretro-
viral medications and capacity gaps related to viral load
and resistance monitoring). Programme monitoring and
research is also needed on implementation barriers at sites
that continue to operate under previous guidelines.
Several study limitations should be noted. The survey data
were self-reported. Accordingly, in some instances, recall bias
and social desirability bias may have led to inaccurate
responses and/or responses more closely aligned with
national treatment guidelines and norms than true practice.
HIV care and treatment sites participating in IeDEA are pri-
marily public-sector health facilities, and they comprise a
heterogeneous mix of academic and community-based hospi-
tals and health centres [16]. However, IeDEA-participating
sites are unlikely to be representative of all HIV care clinics
in a given country. Moreover, in countries where one site
completed the survey on behalf of a larger network of sites,
there may be greater heterogeneity in site-level practices
than is reflected in the survey results. Accordingly, general
practice related to Treat All implementation in each country
may differ from the results reported here, and the timing of
site-level Treat All introduction and estimates of the median
time from national guideline adoption and site-level introduc-
tion may mask in-country variation.
5 | CONCLUSIONS
Data from this survey indicate that by mid- to late-2017, the
Treat All strategy was being implemented across most IeDEA
sites in 41 countries, including rural, primary-level health facili-
ties in low-resource settings. Further research is needed to
assess patient outcomes and the quality and effectiveness of
HIV-related care under Treat All and to identify bottlenecks
Table 3. (Continued)
Counseling sessions prior to ART
initiation Timing of ART initiation
Viral loada
testing routinely
available N (%)
0 sessions
N (%)
1 to 2
sessions
N (%)
≥3 sessions
N (%)
Same day
start N (%)
1 to 14 days
N (%)
2 to 4 weeks
or >1 month
N (%)
After WHO
recommendation
1 (1%) 62 (60.2%) 40 (38.8%) 53 (53.0%) 40 (40.0%) 7 (7.0%) 49 (49.0%)
Treat All not adopted nationally 0 (0%) 13 (86.7%) 2 (13.3%) 5 (27.8%) 9 (50.0%) 4 (22.2%) 13 (72.2%)
aQuantitative PCR or viral load assay available for routine use; bsites in countries that adopted Treat All in 2017 after the survey was completed
counted among sites where Treat All was not yet adopted nationally; ctiming relative to WHO recommendation of September 2015.
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that contribute to ongoing delays in ART initiation and other
suboptimal patient outcomes. However, the accelerating roll-
out of Treat All at HIV care and treatment sites across IeDEA
is promising for the achievement of UNAIDS’ 95-95-95 tar-
gets to end the AIDS epidemic.
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